Skip to content
10-Q

Quarterly Report

DRUGS MADE IN AMERICA ACQUISITION CORP. DMAA DMAAR DMAAU

0001213900-26-056798

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 24.28M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$91.25K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$251.24K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.89K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $6.14K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$7.38M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$7.26M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$7.18M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$244.85K
Current Liabilities Q1 2026 · Mar 31, 2026 $492.17K
Current Liabilities Q1 2026 · Dec 31, 2025 $376.17K
Total Liabilities Q1 2026 · Mar 31, 2026 $7.39M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.28M
Current Assets Q1 2026 · Mar 31, 2026 $14.89K
Current Assets Q1 2026 · Dec 31, 2025 $12.19K
Total Assets Q1 2026 · Mar 31, 2026 $242.04M
Total Assets Q1 2026 · Dec 31, 2025 $239.92M
Sga Expense Q1 2026 · Mar 31, 2026 $143.3K
Sga Expense Q1 2026 · Mar 31, 2025 $330.93K
Net Income Q1 2026 · Mar 31, 2026 $1.97M
Net Income Q1 2026 · Mar 31, 2025 $1.25M
Operating Income Q1 2026 · Mar 31, 2026 −$143.3K
Operating Income Q1 2026 · Mar 31, 2025 −$330.93K